Jasper Therapeutics (NASDAQ:JSPR) Shares Down 7.3% – What’s Next?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) fell 7.3% during trading on Monday . The company traded as low as $1.6050 and last traded at $1.64. 852,758 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 3,774,549 shares. The stock had previously closed at $1.77.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on JSPR shares. JMP Securities reduced their price target on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Monday, September 22nd. BTIG Research cut their price target on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Wednesday, October 8th. Finally, Evercore ISI dropped their price target on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a research note on Monday, September 22nd. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.29.

Jasper Therapeutics Stock Down 7.3%

The stock has a market capitalization of $45.89 million, a price-to-earnings ratio of -0.28 and a beta of 3.06. The company has a 50 day simple moving average of $2.01 and a 200-day simple moving average of $3.08.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Monday, November 10th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12). As a group, sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Judith Anne Shizuru acquired 41,000 shares of the company’s stock in a transaction on Monday, September 22nd. The shares were acquired at an average cost of $2.43 per share, for a total transaction of $99,630.00. Following the purchase, the director owned 156,901 shares in the company, valued at approximately $381,269.43. The trade was a 35.38% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Svetlana Lucas acquired 20,000 shares of Jasper Therapeutics stock in a transaction on Monday, September 22nd. The stock was purchased at an average cost of $2.43 per share, with a total value of $48,600.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at $48,600. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 143,000 shares of company stock worth $347,490 over the last 90 days. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Nuveen LLC purchased a new stake in shares of Jasper Therapeutics during the 1st quarter valued at $440,000. T. Rowe Price Investment Management Inc. boosted its position in shares of Jasper Therapeutics by 755.3% in the first quarter. T. Rowe Price Investment Management Inc. now owns 702,757 shares of the company’s stock valued at $3,022,000 after acquiring an additional 620,592 shares during the period. Kingdon Capital Management L.L.C. increased its holdings in shares of Jasper Therapeutics by 9.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 490,000 shares of the company’s stock worth $2,107,000 after purchasing an additional 43,000 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Jasper Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock worth $1,005,000 after purchasing an additional 23,453 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Jasper Therapeutics in the 1st quarter worth approximately $46,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.